ABSTRACT
Background Many genetic variants and multiple environmental factors increase risk for schizophrenia (SZ). SZ-associated genetic variants and environmental risk factors have been associated with altered DNA methylation (DNAm), the addition of a methyl group to a cytosine in DNA. DNAm changes, acting through effects on gene expression, represent one potential mechanism by which genetic and environmental factors confer risk for SZ and alter neurobiology.
Methods We investigated the hypothesis that DNAm in superior temporal gyrus (STG) is altered in SZ. We measured genome-wide DNAm in postmortem STG from 44 SZ subjects and 44 non-psychiatric comparison (NPC) subjects using Illumina Infinium MethylationEPIC BeadChip microarrays. We applied tensor composition analysis to extract cell type-specific DNAm signals.
Results We found that DNAm levels differed between SZ and NPC subjects at 242 sites, and 44 regions comprised of two or more sites, with a false discovery rate cutoff of q=0.1. We determined differential methylation at nine of the individual sites were driven by neuron-specific DNAm alterations. Glia-specific DNAm alterations drove the differences at two sites. Notably, we identied SZ-associated differential methylation within within mitotic arrest deficient 1-like 1 (MAD1L1), a gene strongly associated with SZ through genome-wide association studies.
Conclusions This study adds to a growing number of studies that implicate DNAm, and epigenetic pathways more generally, in SZ. Our findings suggest differential methylation may contribute to STG dysfunction in SZ. Future studies to identify the mechanisms by which altered DNAm, especially within MAD1L1, contributes to SZ neurobiology are warranted.
INTRODUCTION
Schizophrenia (SZ) is a severe neuropsychiatric disorder with complex etiology. Heritability estimates for SZ from twin studies are consistently ∼80% (1), thus suggesting a substantial genetic contribution to its etiology. Genome-wide association studies (GWAS) have identified many common variants associated with SZ, although each variant has only a small effect on risk for the disorder (2). A recent large-scale GWAS meta-analysis identified such variants at 145 distinct genetic loci (3). Heritability estimates from GWAS fall short of those predicted by twin studies, thus suggesting that other forms of genetic variation contribute risk for SZ. Indeed, recent studies have found a high burden of both rare single nucleotide variants and rare copy number variants in subjects with SZ (4,5). Multiple environmental factors have also been found to contribute to SZ etiology including, among others, maternal infections and malnutrition during pregnancy and obstetric complications (6).
SZ-associated genetic variation and environmental factors associated with SZ risk have both been found to alter DNA methylation (DNAm) (7–11). DNAm, the addition of a methyl group to a cytosine in DNA, stably affects gene experession via interaction with transcription factor binding (12). DNAm is associated with both increased and decreased gene expression as well as other forms of gene regulation, including splicing and alternative promoter usage (12–14). Changes in DNAm, acting through effects on gene expression, represent one potential mechanism by which both genetic and environmental factors can confer risk for SZ and alter brain development and biology.
The superior temporal gyrus (STG) is a region of the brain critical for auditory processing. In individuals with SZ, altered STG function is associated with auditory verbal hallucinations and impaired auditory sensory processing. Impaired auditory processing further contributes to phonologic dyslexia and difficulty recognizing and expressing spoken emotional tone (prosody) in SZ (15). In this study, we investigated the hypothesis that DNAm is altered in the STG from subjects with SZ. To this end, we used Illumina Infinium MethylationEPIC BeadChip microarrays (EPIC arrays) to measure genome-wide DNAm in the STG from 44 subjects with SZ and 44 non-psychiatric comparison (NPC) subjects. Tensor composition analysis (TCA) was used to extract cell type-specific DNAm signals from brain tissue-level data.
MATERIALS AND METHODS
POSTMORTEM BRAINS
Tissue was obtained from postmortem brains recovered and processed as described previously (16,17). Briefly, brains were retrieved during routine autopsies at the Allegheny County Medical Examiner’s Office, Pittsburgh, PA, USA, following informed consent from next-of-kin. An independent committee of experienced clinicians made consensus Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnoses, or determined the absence thereof, based on clinical records and collateral history obtained via structured interviews with surviving relatives (18). The right hemisphere was blocked coronally and the resultant slabs snap frozen and stored at −80°C. Slabs containing the STG were identified and the STG was removed as a single block from each of the slabs in which it was present. Samples containing all six cortical layers of STG (planum temporale), but excluding the adjacent white matter, were harvested. All procedures were approved by the University of Pittsburgh Committee for the Oversight of Research and Clinical Training Involving Decedents and the Institutional Review Board for Biomedical Research.
COHORT MEMBERSHIP
The cohort comprised 44 subjects with either schizophrenia (N=31) or schizoaffective disorder (N=13), and 44 NPC subjects. Subjects diagnosed with schizophrenia and schizoaffective disorder were grouped together for analysis, and referred to as SZ subjects, or the SZ group. In this manuscript, as in our previous studies, we found that the diagnoses do not differ with respect to DNAm (19). Each subject in the SZ group was matched with one NPC subject for sex, hemisphere, and as closely as possible for postmortem interval (PMI), age, and other characteristics (Table 1 and Supplementary Table 1).
DNA PREPARATION AND BISULFITE CONVERSION
DNA (∼10 ug) was isolated from STG gray matter (∼20 mg) using AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Valencia, CA, USA) and bisulfite converted using EZ-96 DNA Methylation Kit (Zymo Research, Irvine, CA, USA), both as per manufacturer’s protocol.
DNA METHYLATION ARRAYS
DNAm is the addition of a methyl group to a cytosine in DNA. DNAm is observed within the context of cytosine-phosphate-guanine dinucleotides (CpGs), most commonly, but also within the context of a cytosine-phosphate-H dinucleotides (CpHs; H=cytosine, adenine, thymine) (20,21). CpGs and CpHs are referred to as ‘DNAm sites’ or ‘sites’ in this manuscript. DNAm was measured at 866,091 sites using MethylationEPIC BeadChip Infinium array (EPIC array; Illumina, San Diego, CA, USA) as per manufacturer’s protocol (22,23). A β-value, the proportion of a particular site that is methylated in a DNA sample, was determined for each site by taking the ratio of the methylated to unmethylated signal, using the formula: β-value = intensity of the methylated signal/(intensity of the unmethylated signal + intensity of the methylated signal + 100). A 96-entry EPIC array was filled with samples from the 88 subjects, including replicate samples from eight subjects. Data is available for download from Gene Expression Omnibus (GEO; GSE144910).
DATA PREPROCESSING AND FILTERING
Data analyses were performed using the R software environment (www.r-project.org). Color adjustment and background correction were performed using the bgAdjust2C method (24). Normalization was performed using the preprocessQuantile function in the R package minfi (25). The initial dataset comprised data from 1,051,815 probes corresponding to 866,091 DNAm sites for each subject. Multidimensional scaling (MDS) was used to visualize the degree of similarity among samples (26). Prior to data filtering, samples segregated strongly by sex in MDS space (Supplemental Figure 1A). Data filtering involved removing all data points associated with a probe if the probe failed detection as indicated by a median detection p-value >0.01 (probes corresponding to 12,350 DNAm sites), cross-reacted with multiple genomic regions (probes corresponding to 39,269 DNAm sites), contained a single nucleotide polymorphism within its binding site (probes corresponding to 27,395 DNAm sites), or interrogated a DNAm site on a sex chromosome (probes corresponding to 18,628 DNAm sites). Data from probes corresponding to 768,449 DNAm sites remained for downstream analysis (Supplemental Figure 2). After data filtering, MDS using data from the 3,000 most variable sites was performed and samples no longer segregated by sex (Supplemental Figure 1B), but segregation by race (Supplemental Figure 1C) and age (Supplemental Figures 1D and 1E) became evident. The replicate sample pairs from each of the eight subjects from which replicate samples were collected and assayed co-segregated in MDS space (Supplemental Figure 1F), thus demonstrating the reproduceability of our approach. The β-values for each replicate pair were averaged for the downstream analyses.
DIFFERENTIAL DNA METHYLATION
Linear regression was used to identify differentially methylated sites (DMSs). DNAm, in the form of preprocessed and normalzed β-values, was the dependent variable and diagnosis was the independent variable. Race, age, and PMI were included as covariates in the analysis. The MDS analysis described above supported the inclusion of race as a covariate. Most subjects in this cohort self-identifed as either white or black, however, one subject self-identified as Asian Indian and, consistent with known genetic architecture (27), clustered with the subjects of European ancestry (Supplemental Figure 1C) and was thus combined with the subjects that self-identified as white for analyses. The inclusion of age as a covariate is supported by the MDS analysis as well as existing literature that shows age has a robust effect on DNAm (28–30). Though samples did not segregate by PMI in MDS space (data not shown), it was included as a covariate because the stability of many molecular measures have been found to be particularly sensitive to PMI (31,32), and to maintain consistency with our previous study in which it was included as a covariate in our primary analyses (19).
Differential methylated regions (DMRs) were identified using the R package DMRcate (33). DMRcate uses an approach based on tunable kernel smoothing of the differential methylation signal across the genome obtained in the site-based differential DNAm analysis described above. A Benjamini–Hochberg corrected false discovery rate (FDR) <0.1 for the smoothed signal was considered significant. Then regions with a maximum of 1000 basepairs containing at least two such significant sites were defined as DMRs.
NEURON AND GLIA PROPORTION ESTIMATES
The proportion of neurons and glia in each sample was estimated with CETS, an R package that uses β-values from cell type-specific sites to generate the estimation (34).
NEURON- AND GLIA-SPECIFIC DIFFERENTIAL DNA METHYLATION
The CETS-estimated proportions of neurons and glia for each subject and tensor composition analysis (TCA) (35) were used to estimate the subject-level neuron- and glia-specific β-values for each DNAm site and detect sites at which DNAm differs between subjects with SZ and NPC subjects. The cell type proportions were refit in TCA and adjusted for age, race, and PMI.
RESULTS
SZ-associated differential DNA methylation was identified at many individual sites and genomic regions
DNAm differed between subjects with SZ and NPC subjects at more sites than would be expected by chance (Figure 1A). DNAm differed at 242 sites between subjects with SZ and NPC subjects with an FDR cutoff of q=0.1 (Table 2). Of these 242 differntially methylated sites (DMSs), DNAm differed at 101 with a FDR cutoff of q=0.05. No global differences in DNAm were identified between SZ and NPC subjects (Supplemental Figure 3). The sites at which DNAm differed between subjects with SZ and NPC subjects were broadly distributed across all autosomes (Figure 1B).
(A) Probability plot showing that the analysis for sites at which DNAm differed between SZ and NPC subjects is enriched in small p-values compared to what would be expected by chance. The y=x line represents the distribution of p-values than would be expected by chance. (B) Manhattan plot showing that the DNAm differed between subjects with SZ and NPC subjects at many DNAm sites, and the sites were distributed across many autosomes. The horizontal lines represent FDR cutoff of q=0.1 (bottom) and q=0.05 (top). DNAm, DNA methylation; SZ, schizophrenia; NPC, non-psychiatric comparison; FDR, false discovery rate.
The 242 sites at which DNAm differed between SZ and NPC subjects with the FDR cutoff of q=0.1 (adjusted for age, race and PMI) are listed in the table. Abbreviations: DNAm, DNA methylation; NPC, non-psychiatric comparison; PMI, postmortem interval; SZ, schizophrenia.
DNAm is known to differ markedly between neurons and glia (36), and detection of DNAm differences between groups in tissue with multiple cell types can be confounded by cell composition. In STG samples studied here, neuronal proportion did not differ between subjects with SZ and NPC subjects (SZ=0.46 ±0.05; NPC=0.46 ±0.04; p=0.50) (Supplemental Table 2A), and we have previously shown that pyramidal neuron number in layer 3 of this brain region did not differ between subjects with SZ and NPC subjects (37). After adjusting for neuron proportion, DNAm differed at 256 sites between SZ and NPC subjects with the FDR cutoff of q=0.1 (Supplemental Table 2B). Of these 256 sites, 210 were among the 242 detected prior to adjusting for neuron proportion thus suggesting that cell composition does not account for the majority of observed differences in DNAm.
Genomic regions in which DNAm at multiple contiguous sites differs between SZ and NPC subjects, or differentially methylated regions (DMRs), may be more biologically meaningful or have different functional consequences than those of a single DMS. There were 44 genomic regions in which DNAm at two or more contiguous, measured sites differed between subjects with SZ and NPC subjects (Table 3).
The 44 genomic regions in which DNAm differed at two or more contiguous, measured sites between SZ and NPC subjects are listed. Abbreviations: DNAm, DNA methylation; DMR, differentially methylated region; SZ, schizophrenia; NPC, non-psychiatric comparison; bp, base pairs.
Of note, three DMSs and one DMR were identified within mitotic arrest deficient 1-like 1 (MAD1L1), a gene strongly associated with SZ through genome-wide association studies (3). The MAD1L1-associated differential methylation we identified spanned a portion of intron 2 and exon 3, and the DNAm levels were lower in SZ subjects relative to NPC subjects.
SZ-associated differential DNA methylation at some individual sites was specific to neurons or glia
Cell type deconvolution identified nine differentially methylated sites in neurons (Figure 2A and 2C) and two differentially methylated sites in glia (Figure 2B and 2C) with an FDR cutoff of q=0.1. All 11 sites for which DNAm differed between SZ and NPC subjects in cell type-specific manner were also identified as being differentially methylated in the bulk tissue analysis (Table 2).
(A) Manhattan plot showing neuron-specific DNAm differences between SZ and NPC subjects at nine sites. (B) Manhattan plot showing glia-specific DNAm differences between SZ and NPC subjects at two sites. (C) Box plots of DNAm (β-value) at sites of cell type-specific differences in DNAm between SZ and NPC subjects. DNAm, DNA methylation; SZ, schizophrenia; NPC, non-psychiatric comparison.
DISCUSSION
In the STG of SZ subjects, we indentified DNAm differences at 242 individual sites and 44 genomic regions with multiple sites. Notably, we found SZ-associated differential methylation in MAD1L1, a gene that harbors a single nucleotide polymorphism (SNP) that strongly associates with SZ (third out of 145 loci that reached genome-wide significance) in the largest meta-analysis of genome-wide association studies to date from the Schizophrenia Working Group of the Psychiatric Genomics Consortium (3). The MAD1L1-associated differential methylation we identified was characterized by lower DNAm in SZ subjects relative to NPC subjects, a difference we determined to be driven by neuron-specific alterations in DNAm. This finding is consistent with studies in the prefrontal cortex that also identified genome-wide significant DMRs in MAD1L1 (10).
Despite strong evidence implicating MAD1L1 in SZ, the underlying mechanisms through which MAD1L1-associated SNPs and differential methylation might contribute to SZ neurobiology are unclear. MAD1L1 is expressed in many human tissues (39,40), and is known to have a role in regulating the spindle assembly checkpoint during mitosis (41). Genetic mutations that disrupt MAD1L1 expression are associated with aneuploidy and multiple cancers (39,40). During development MAD1L1 is most strongly expressed in differentiating cells and is critical for the transition from proliferation to terminal differentiation in a broad range of cell types (42,43). Given MAD1L1 is expressed in both neurons and glia of most brain regions (44–46), the differentiation of neurons and glia may be disrupted if MAD1L1 expression is affected by SZ-associated differential methylation during neurodevelopment. Such a disruption would be predicted to alter the delicate balance of the various neuronal and glia subtypes and thus brain circuitry, perhaps giving rise to the dysfunctional brain circuits that are associated with the clinical features of SZ (47).
Alternatively, MAD1L1 may act post-neurodevelopment as its expression in terminally differentiated cells, including post-mitotic neurons and glia, suggests a function in addition to those related to development. Studies have found that its expression in terminally differentiated cells may be necessary for maintaining the differentiated state (48–50). Indeed, even modest decreases in MAD1L1 expression leads to dedifferentiation in some cell types (48). Some evidence points to a role for dedifferentiation of post-mitotic neurons in the cognitive decline and behavioral changes associated with normal brain aging in humans (51–53), and a similar mechanism could conceivably contribute to SZ neurobiology. That said, these proposed mechanisms are conjecture and critical next steps should focus on understanding MAD1L1 in the brain, generally, and translating MAD1L1-associated SNPs and differential methylation into molecular mechanisms for SZ, specifically.
This study is the first to identify SZ-associated differential methylation in the STG. Others have previously reported DNAm differences between subjects with SZ and NPC subjects in the prefrontal cortex (10,38,54–56), striatum (54), hippocampus (54,57), and cerebellum (54) thus suggesting that altered DNAm in multiple brain regions contributes to SZ neurobiology. Our findings add to the growing body of literature that implicates altered epigenetic pathways, including DNAm as well as histone modifications (58–60), in SZ neurobiology. Though most often studied separately, there is extensive crosstalk between DNAm and histone modification pathways (61–63). This crosstalk drives the establishment of composite epigenetic signatures that depend on epigenetic regulatory enzymes (e.g., DNA methyltransferases, histone methyltransferases, etc) with protein domains that specifically recognize methylated DNA and/or modified histones and thus allow for linking of DNAm and histone modifications at appropriate sites in the genome. SETD1A, a gene in which loss-of-function mutations confer a large increase in risk for SZ (64), is an example of an enzyme linking DNAm and histone modification. SETD1A methylates histones after it is localized to unmethylated DNA via an interaction with CXXC-finger protein-1 (65). This body of literature suggests that a more complete understanding of how these epigenetic pathways and their interactions are altered in SZ is likely to be fruitful in identifying molecular mechanisms contributing to SZ. Epigenetic editing technologies that use highly specific DNA-targeting tools (e.g., CRISPR) to methylate DNA or modify histones in a locus-specific manner will be valuable in dissecting these molecular mechanisms in cell culture and animal models (66,67).
Our findings in this study, like those of all postmortem brain studies, are only correlative and cannot establish causal relationships. The causes of the SZ-associated differences in DNAm that we identified in the STG are likely a combination of genetic and environmental factors. Methylation quantitative trait loci are common genetic variants that influence DNAm levels at sites in a particular genomic region, and they are common in the brain (68). However, none of the differentially methylated loci identified in this study have been shown to be associated with genetic variants that overlap with SZ risk loci (10,54), or are known to be altered by environmental risk factors for SZ like perinatal famine (11).
Though differential methylation may be associated with SZ risk factors, it may be the result of exposure to antipsychotics or others confounds. Studies of peripheral tissues indicate that antipsychotics do alter DNAm (69). However, DNAm alterations are already present in subjects with only brief (<16 weeks) antipsychotic treatment (70), thus suggesting that much SZ-associated differential methylation is intrinisic to the illness. Some studies have even found that SZ-associated DNAm alterations in peripheral tissues are normalized by treatment with antipsychotics (71), raising the possibility that the therapeutic effects of antipsychotics are mediated, in part, by DNAm changes. Such findings also make it likely that antipsychotics mask some SZ-associated differential methylation from being detected in studies.
An additional potential confound particularly relevant in studies of DNAm in subjects with SZ is cigarette smoking. Cigarette smoking is much more common among individuals with SZ than the general population and is known to induce robust DNAm changes in peripheral tissues (72). The effect of cigarette smoking on DNAm in the brain has not been studied. However, none of the differentially methylated sites or regions identified in this study have been found to be among the sites most strongly affected by cigarette smoking in peripheral tissues.
This study lays the groundwork for more detailed investigations of SZ-associated differential methylation in the STG. Future studies should focus identifying the mechanisms by which altered DNAm, especially within MAD1L1, contributes to SZ neurobiology. To this end, studies that use of epigenetic editing technology to recapitulate SZ-associated differential methylation in cell cultures and animal models will be useful. Also of value will be studies that use a multi-omics approach for understanding the dynamic interaction among epigenome, transcriptome, and genetic variation in the STG.
Data Availability
Data is available for download from Gene Expression Omnibus (GEO; GSE144910)
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144910
FUNDING AND DISCLOSURES
This work was supported by NIH Grants K23 MH112798 (BCM) and R01 MH071533, MH116046, and AG027224 (RAS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, or the United States Government. DAL currently receives investigator-initiated research support from Pfizer and Merck. All the other authors declare no competing interests.
Footnotes
Express Mail: Biomedical Science Tower, Room W-1658, Lothrop and Terrace Streets, Pittsburgh, PA 15213-2593